GP co-payment: Friend or foe for Primary Health Care Limited?

GP co-payment is tipped to spell the death of bulk billing. Can the bulk billing model of Primary Health Care Ltd (ASX: PRY) survive?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The introduction of a $5 co-payment on GP (doctors) visits has led to suggestions that bulk billing is dead, which could spell trouble for Primary Health Care Limited (ASX: PRY) as its business model is based on this. So how is this measure likely to affect the company?

The measure is widely expected to lead patients to delay or even avoid visiting GPs. This would imply reduced volume for the industry, and hence lower revenue for all players.

The government is also looking to extend the freeze on rebate indexation to four years till June 2018. The last time there was a freeze in rebate indexation was under the Howard government between 1996 and 2003. This prompted bulk bill doctors to switch to private billing, with bulk billing felling from 80.6% to 68.5% during the period.

On the face of it this sounds very negative, but it is actually a great opportunity for the company to gain market share.

The Doctors Reform Society predicts private billing GP fees will exceed $100 within two years under current changes – which means the out-of-pocket expense will reach a whopping $67.95. If this is indeed true then it is highly likely that existing private billing patients would opt for bulk-bill doctors.

Also, many in the medical community have predicted that the changes will push more patients to visit the emergency department of the general hospital system. Whilst patients can save $5 to see a doctor in this fashion, the fact that 1) the wait time will be horrendously long & 2) there will be no continuity in care as they're likely to be seen by a different doctor each time means that seeing a GP is likely to be money well spent.

Further it is plausible that not all doctors that convert to private billing will survive in that new form. According to the Australian Medical Association, average out-of-pocket expenses borne by patients for a GP visit are around $28 – equating to GP fees of around $60. However increased competition could lower this amount, even though the association suggests that the adequate price for GP service should actually be $75. Without the higher volumes under bulk billing, it is unclear if these GPs can remain profitable under private billing.

In this situation one possible scenario is for doctors to exit the profession. However this is highly unlikely given it takes at least eight years of education & residency to become a doctor, and they're unlikely to enter another profession that is as financially and personally rewarding. This presents a great opportunity for Primary Health Care to hire additional experienced doctors in their large scale centres as well as snap up more medical centres on the cheap.

The third change the government is looking to introduce is a further reduced rebate for consultations less than 10 minutes. Large medical centres like Primary's have been criticised for quickly churning patients to improve margins. This is unlikely to be a major issue for the company as their average patient time is 14 minutes and 18 seconds – based on observations it conducted over a year in a centre with twenty doctors.

So far the analysis has centred on the company passing on the $5 rebate cut to patients, but this choice actually rests with the GPs. It needs to be noted that pathology and imaging services are sourced from GP referrals, a key reason why the major players in these markets operate their own network of medical centres.

Given the impressive margins of the company's medical centre operations, it could opt not to pass on the rebate cut to patients. Not only will this allow the company to grab an even larger slice of the bulk billing market, but it could also increase market share in its pathology and imaging businesses by boosting their volumes.

Foolish Takeaway

It is unclear if there will be further changes to the co-payment proposal, or how strongly GPs – especially bulk billed, will be affected. However it would appear that Primary Health Care is well placed to grow its medical centre and associated businesses in a co-payment environment. With a P/E of 14.6x it should at least be on your watchlist.

Motley Fool contributor Simon Chan does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »